Completed PHASE2 INTERVENTIONAL 2-arm NCT01919723

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention

Sponsor: AstraZeneca

Conditions Acute Coronary Syndrome

Interventions Eptifibatide Ticagrelor

Updated 6 times since 2017 Last updated: Jan 9, 2017 Started: Feb 28, 2014 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01919723, this PHASE2 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Completed PHASE2

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University of Alabama at Birmingham

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States
• Cincinnati, United States